How to promote vaccinations: a pilot study in the North-West of Italy

Background: vaccines are one of the greatest medical discoveries. In various countries, pharmacists are authorised to administer vaccines directly in pharmacies; thus, leading to an increase in the immunisation rate and a notable gain in consensus amongst the population. The main objective was to evaluate the opinion of pharmacy customers regarding the proposal to authorise pharmacies to administer vaccines. Results: 85% of the respondents were in favour of the introduction of a vaccinating pharmacist. The data show more positive attitudes to the introduction of this service amongst subjects with an elderly dependant relative (PR = 1,10; p = 0.025). Furthermore, it can be noticed a higher probability of positive attitudes to the establishment of the vaccinating pharmacist amongst those with positive attitudes to vaccines (PR = 1,15; p = 0.039). Moreover, the pharmacist is seen as a reference on the subject of vaccines by only 8% of interviewees. Discussion: The data highlight the particularly positive feedback regarding the subject of pharmacists being authorised to administer vaccines. This service may, however, encounter obstacles such as economic problems and opposition from other health professionals. Materials and methods: Data were gathered through a face-to-face interview by means of questionnaires in eight pharmacies in the north-west of Piedmont (Italy). Descriptive statistics were performed. The comparison between the proportions and average values was performed by χ2 and t-test. The indicator used for the associations was the Prevalence Ratio (PR). The PR was calculated using a modified Poisson regression with robust standard errors. The level of significance was fixed at 0.05; IC at 95%

Cannabis for Medical Use: Analysis of Recent Clinical Trials in View of Current Legislation

Cannabis has long been regarded as a recreational substance in the Western world. The recent marketing authorization of some medicinal products of industrial origin and the introduction onto the market of inflorescences for medical use mean that medical doctors can now prescribe Cannabis-based medicines in those countries which allow it. Nevertheless, there is still considerable controversy on this topic in the scientific community. In particular, this controversy concerns: the plant species to be used; the pathologies that can be treated and consequently the efficacy and safety of use; the routes of administration; the methods of preparation; the type and dosage of cannabinoids to be used; and, the active molecules of interest. As such, although medical Cannabis has been historically used, the results of currently completed and internationally published studies are inconclusive and often discordant. In light of these considerations, the aim of this work is to analyse the current legislation in countries that allow the use of medical Cannabis, in relation to the impact that this legislation has had on clinical trials. First of all, a literature search has been performed (PubMed and SciFinder) on clinical trials which involved the administration of Cannabis for medical use over the last 3 years. Of the numerous studies extrapolated from the literature, only about 43 reported data on clinical trials on medical Cannabis, with these mainly being performed in Australia, Brazil, Canada, Denmark, Germany, Israel, Netherlands, Switzerland, the United Kingdom and the United States of America. Once the reference countries were identified, an evaluation of the legislation in relation to Cannabis for medical use in each was carried out via the consultation of the pertinent scientific literature, but also of official government documentation and that of local regulatory authorities. This analysis provided us with an overview of the different legislation in these countries and, consequently, allowed us to analyse, with greater awareness, the results of the clinical trials published in the last 3 years in order to obtain general interest indications in the prosecution of scientific research in this area

Proteostasis Regulators in Cystic Fibrosis: Current Development and Future Perspectives

In cystic fibrosis (CF), the deletion of phenylalanine 508 (F508del) in the CF transmembrane conductance regulator (CFTR) leads to misfolding and premature degradation of the mutant protein. These defects can be targeted with pharmacological agents named potentiators and correctors. During the past years, several efforts have been devoted to develop and approve new effective molecules. However, their clinical use remains limited, as they fail to fully restore F508del-CFTR biological function. Indeed, the search for CFTR correctors with different and additive mechanisms has recently increased. Among them, drugs that modulate the CFTR proteostasis environment are particularly attractive to enhance therapy effectiveness further. This Perspective focuses on reviewing the recent progress in discovering CFTR proteostasis regulators, mainly describing the design, chemical structure, and structure-activity relationships. The opportunities, challenges, and future directions in this emerging and promising field of research are discussed, as well

Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians

Pancreatic cancer (PC) would become the second leading cause of cancer death in the near future, despite representing only 3% of new cancer diagnosis. Survival improvement will come from a better knowledge of risk factors, earlier diagnosis, better integration of locoregional and systemic therapies, as well as the development of more efficacious drugs rising from a deeper understanding of disease biology. For patients with unresectable, non-metastatic disease, combined strategies encompassing primary chemotherapy and radiation seems to be promising. In fit patients, new polychemotherapy regimens can lead to better outcomes in terms of slight but significant survival improvement associated with a positive impact on quality of life. The upfront use of these regimes can also increase the rate of radical resections in borderline resectable and locally advanced PC. Second line treatments showed to positively affect both overall survival and quality of life in fit patients affected by metastatic disease. At present, oxaliplatin-based regimens are the most extensively studied. Nonetheless, other promising drugs are currently under evaluation. Presently, in addition to surgery and conventional radiation therapy, new locoregional treatment techniques are emerging as alternative options in the multimodal approach to patients or diseases not suitable for radical surgery. As of today, in contrast with other types of cancer, targeted therapies failed to show relevant activity either alone or in combination with chemotherapy and, thus, current clinical practice does not include them. Up to now, despite the fact of extremely promising results in different tumors, also immunotherapy is not in the actual therapeutic armamentarium for PC. In the present paper, we provide a comprehensive review of the current state of the art of clinical practice and research in PC aiming to offer a guide for clinicians on the most relevant topics in the management of this disease

The XMM-Newton survey of the ELAIS-S1 field II: optical identifications and multiwavelength catalogue of X-ray sources

We present optical identifications and a multi-band catalogue of a sample of 478 X-ray sources in the XMM and Chandra surveys of the central 0.6 deg^2 of the ELAIS-S1 field. The optical/infrared counterpart of each X-ray source was identified using R and IRAC 3.6 um bands. This method was complemented by the precise positions obtained through Chandra observations. Approximately 94% of the counterparts are detected in the R band, while the remaining are blank fields in the optical down to R~24.5, but have a near-infrared counterpart detected by IRAC within 6 arcsec from the XMM centroid. The multi-band catalogue contains photometry in ten photometric bands (B to the MIPS 24 um). We determined redshift and classification for 237 sources (~50% of the sample) brighter than R=24. We classified 47% of the sources with spectroscopic redshift as broad-line active galactic nuclei (BL AGNs) with z=0.1-3.5, while sources without broad-lines are about 46% of the spectroscopic sample and are found up to z=2.6. We identified 11 type 2 QSOs among the sources with X/O>8, with z=0.9-2.6, high 2-10 keV luminosity (log(L2-10keV)>=43.8 erg/s) and hard X-ray colors suggesting large absorbing columns at the rest frame (logN_H up to 23.6 cm^-2). BL AGNs show on average blue optical-to-near-infrared colors, softer X-ray colors and X-ray-to-optical colors typical of optically selected AGNs. Conversely, narrow-line sources show redder optical colors, harder X-ray flux ratio and span a wider range of X-ray-to-optical colors. On average the SEDs of high-luminosity BL AGNs resemble the power-law typical of unobscured AGNs. The SEDs of NOT BL AGNs are dominated by the galaxy emission in the optical/near-infrared, and show a rise in the mid-infrared which suggests the presence of an obscured active nucleus.Comment: 15 pages, A&A accepted, affiliations correcte

Motor Outcome Measures in Pediatric Patients with Congenital Muscular Dystrophies: A Scoping Review

Congenital muscular dystrophies (CMDs) are a heterogeneous group of genetic neuromuscular disorders. They usually occur at birth or in early childhood, with delayed acquisition of motor milestones, and diffuse muscle weakness. A dystrophic pattern is evident on the muscle biopsy. They are highly variable both in terms of severity and clinical evolution and in terms of pathogenetic biochemical mechanisms. The aim of this review is to collect and summarize the current knowledge of motor function in pediatric patients with congenital muscular dystrophies and the instruments used to assess it. This scoping review was conducted using the methodology of PRISMA (extension for Scoping Reviews, PRISMA-ScR). Two databases were queried from January 2002 to November 2022. Articles were identified based on title and abstract. Full-text papers published in peer-reviewed English-language journals were selected. It emerged that motor functional aspects are still underinvestigated in CMD patients, probably due to the rarity of these conditions and the phenotypic variability. The scales used to assess motor function are heterogeneous, as are the age groups considered. Finally, the predominant type of research design is cross-sectional; few studies analyze the progression of motor function over time. All these factors make it difficult to correlate the results of different publications and stress the need for more accurate and shared protocols for assessing motor function in these patients

A wide angle tail radio galaxy in the COSMOS field: evidence for cluster formation

We have identified a complex galaxy cluster system in the COSMOS field via a wide angle tail (WAT) radio galaxy consistent with the idea that WAT galaxies can be used as tracers of clusters. The WAT galaxy, CWAT-01, is coincident with an elliptical galaxy resolved in the HST-ACS image. Using the COSMOS multiwavelength data set, we derive the radio properties of CWAT-01 and use the optical and X-ray data to investigate its host environment. The cluster hosting CWAT-01 is part of a larger assembly consisting of a minimum of four X-ray luminous clusters within ~2 Mpc distance. We apply hydrodynamical models that combine ram pressure and buoyancy forces on CWAT-01. These models explain the shape of the radio jets only if the galaxy's velocity relative to the intra-cluster medium (ICM) is in the range of about 300-550 km/s which is higher than expected for brightest cluster galaxies (BCGs) in relaxed systems. This indicates that the CWAT-01 host cluster is not relaxed, but is possibly dynamically young. We argue that such a velocity could have been induced through subcluster merger within the CWAT-01 parent cluster and/or cluster-cluster interactions. Our results strongly indicate that we are witnessing the formation of a large cluster from an assembly of multiple clusters, consistent with the hierarchical scenario of structure formation. We estimate the total mass of the final cluster to be approximately 20% of the mass of the Coma cluster.Comment: 18 pages, 13 figures; accepted for publication in ApJS, COSMOS special issue; added color figure (Fig. 13) which was previously unavailabl